SS-31 Peptide: What Is It Studied For?

What Is SS-31?

SS-31 is a synthetic tetrapeptide, also known by its clinical name elamipretide, designed to selectively accumulate in the inner mitochondrial membrane and stabilize cardiolipin — a phospholipid critical to mitochondrial architecture and energy production. The compound belongs to a class of aromatic-cationic peptides characterized by alternating aromatic and positively charged amino acid residues. That structural pattern allows it to cross biological barriers that block most large molecules, including the blood-brain barrier. Research on SS-31 spans both preclinical animal models and registered human trials, with studies published under both names.

---

What Is SS-31 Studied For?

Research on SS-31 goes back to 2020 — 6 years — with studies continuing through 2025.

1. Neuroinflammation and Memory Impairment — A 2020 mouse preclinical study reported that SS-31 attenuated mitochondrial dysfunction, reduced synaptic damage, and improved memory performance in animals subjected to lipopolysaccharide-induced neuroinflammation.

2. Spinal Cord Injury Neuroprotection — A 2023 rodent preclinical study found that SS-31 suppressed a form of inflammatory cell death called pyroptosis in traumatically injured spinal cord tissue by inhibiting cPLA2-driven lysosomal membrane permeabilization.

3. Cardiac Protection After Ischemia-Reperfusion — A 2025 preclinical study using cardiomyocyte cell cultures subjected to hypoxia/reoxygenation found that a combination formulation built around SS-31 reduced ferroptotic cell death through mitochondrial targeting.

4. Myocardial Infarction Recovery — A 2022 rodent preclinical study demonstrated that sustained delivery of SS-31 via a reactive oxygen species–responsive hydrogel improved mitochondrial function in cardiomyocytes and supported angiogenesis in an infarction model.

5. Primary Mitochondrial Myopathy and Barth Syndrome — Human Trials — A randomized clinical trial enrolling 218 participants (MMPOWER-3, 2023) evaluated SS-31/elamipretide in individuals with primary mitochondrial myopathy, and a separate 168-week open-label extension of the TAZPOWER trial reported long-term safety and efficacy data in Barth syndrome patients — the most extensive human dataset currently available for this compound.

---

How Does SS-31 Work?

SS-31's mechanism centers on cardiolipin, a dimeric phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin normally stabilizes the electron transport chain complexes that generate ATP; under oxidative stress, it becomes peroxidized, which destabilizes those complexes and amplifies reactive oxygen species (ROS) production. SS-31 binds directly to cardiolipin, reducing its peroxidation and preserving the structural integrity of the inner membrane.

Because cardiolipin carries a net negative charge, the alternating cationic residues in SS-31's backbone drive electrostatic accumulation at the inner membrane — concentrating the compound precisely where mitochondrial damage initiates. The 2020 mouse study on lipopolysaccharide-induced memory impairment attributed SS-31's downstream neurological effects to this upstream mitochondrial stabilization. The 2023 spinal cord injury rodent study similarly traced the compound's anti-pyroptotic action to prevention of lysosomal membrane permeabilization triggered by lipid peroxidation products, a pathway that originates at dysfunctional mitochondria.

---

What Does Animal Research Show?

Preclinical work has tested SS-31 across four distinct injury and disease models, with each model illuminating a different aspect of mitochondrial pathology.

Neuroinflammation model. The 2020 mouse preclinical study (PMID 31747905) induced neuroinflammation using systemic lipopolysaccharide and measured mitochondrial morphology, synaptic marker expression, and spatial memory performance. SS-31 treatment was associated with preserved mitochondrial ultrastructure and reduced markers of synaptic loss. The study positioned the compound's benefit as upstream of the cognitive readouts — mitochondrial stabilization preceding the neuronal functional outcomes.

Spinal cord injury model. The 2023 rodent preclinical study (PMID 36609266) focused on traumatic spinal cord injury, where the blood-brain barrier typically limits drug delivery. Investigators specifically noted that SS-31's alternating aromatic-cationic structure allows passive crossing of this barrier — a pharmacokinetic property relevant to any CNS application. The study reported reduced inflammasome activation and decreased pyroptotic markers in injured cord tissue, attributed to cPLA2 inhibition and downstream preservation of lysosomal membrane integrity.

Cardiac ischemia-reperfusion model. The 2025 in vitro and preclinical study (PMID 39848110) tested SS-31 formulated together with the ferroptosis inhibitor ferrostatin-1 in H9C2 cardiomyocyte cells under hypoxia/reoxygenation conditions. The combination reduced mitochondrial membrane potential collapse and lipid peroxidation markers more effectively than either agent alone, suggesting additive effects when mitochondrial-targeted antioxidation is paired with ferroptosis pathway blockade.

Myocardial infarction model. The 2022 rodent study (PMID 35848825) tested sustained local delivery of SS-31 via an injectable hydrogel engineered to release drug in response to elevated ROS — the oxidative environment that characterizes ischemic tissue. Treated animals showed improved ejection fraction and reduced infarct size compared with controls, with histological evidence of increased vasculogenesis in the border zone. The delivery vehicle itself was part of the experimental design, so the results reflect a drug-device combination rather than SS-31 alone.

Diabetic kidney disease model. The 2024 rodent and cell preclinical study (PMID 38200543) examined mitochondrial injury in podocytes — the filtration cells of the kidney — in a diabetic disease model. Abnormal cardiolipin remodeling driven by the enzyme ALCAT1 was identified as a central mechanism of podocyte damage; SS-31 treatment stabilized cardiolipin and attenuated mitochondrial injury markers, though functional kidney outcomes were not the primary endpoint.

Dry eye disease model. The 2024 preclinical study (PMID 38725011) integrated SS-31 into a nanoparticle delivery system designed to penetrate the ocular surface barrier. In a rodent dry eye model, the formulation reduced inflammatory cytokines, oxidative stress markers, and mitochondrial damage in corneal epithelial tissue. As with the cardiac hydrogel study, the delivery platform was a co-variable in the experimental design.

Taken together, preclinical findings consistently implicate cardiolipin stabilization as the proximal mechanism, with tissue-protective effects appearing across neural, cardiac, renal, and ocular contexts — though the magnitude and durability of effects depend substantially on the delivery method used.

---

What Do Human Studies Show?

Human trial data for SS-31/elamipretide come from two registered programs targeting rare mitochondrial disorders. Two of the eight primary studies in this area were published in the Journal of Neuroinflammation; the human trial data, by contrast, appeared in Neurology and Genetics in Medicine, reflecting the distinct research communities involved.

MMPOWER-3. The largest human dataset currently available is the MMPOWER-3 randomized clinical trial (PMID 37268435), which enrolled 218 participants with primary mitochondrial myopathy (PMM) — genetic disorders impairing mitochondrial oxidative phosphorylation. The trial was a phase III design. The primary endpoints addressed physical function and exercise capacity. The published results reported that the trial did not meet its co-primary endpoints of distance walked in a six-minute test and patient-reported fatigue, though secondary and exploratory analyses showed signal in some functional domains. The study represents the most rigorous human efficacy test of SS-31 to date and its results are mixed, underscoring that preclinical mitochondrial findings do not automatically translate to detectable functional benefit in patients with established genetic disease.

TAZPOWER open-label extension. The TAZPOWER trial studied SS-31 in Barth syndrome, a rare X-linked condition involving pathogenic tafazzin mutations that directly disrupt cardiolipin biosynthesis — making it mechanistically the most targeted indication for a cardiolipin-stabilizing peptide. The 168-week open-label extension (PMID 38602181) reported ongoing tolerability and safety data over approximately three years of daily subcutaneous administration, with patients continuing from the original randomized phase. The extension lacked a concurrent placebo arm by design, which limits causal inference for efficacy claims from that period, though the safety profile was characterized as acceptable over the long observation window.

Across both programs, the route of administration was subcutaneous injection, and tolerability was consistently reported as manageable. Neither trial provides a basis for generalizing findings to the healthy or non-genetically affected populations studied in preclinical models.

---

What Is Still Unknown About SS-31?

Several gaps limit the current interpretation of SS-31 research. The human trial results are mixed — MMPOWER-3 missed its co-primary endpoints, and the open-label extension of TAZPOWER lacks a parallel control arm for the extension period — so efficacy in humans at the functional level remains uncertain for even the most mechanistically aligned indications.

All neurological findings (neuroinflammation, spinal cord injury) remain confined to rodent preclinical models. Whether the blood-brain barrier penetration observed in rodents translates to therapeutically relevant CNS concentrations in humans has not been tested in a clinical trial. The two cardiac delivery studies used engineered platforms — a hydrogel and a nanoparticle system — rather than SS-31 in isolation, so their results cannot be attributed to the peptide alone.

The diabetic kidney and dry eye models represent early-stage preclinical work with no corresponding human data in the current literature. Research is active across these areas, but the distance between preclinical proof-of-concept and demonstrated clinical utility remains substantial for most indications.

---

Where Can I Buy SS-31?

SS-31 is available for purchase from BioMax Research at biomaxresearch.com. BioMax Research is a highly regarded source for research peptides, with every product third-party lab tested and backed by a verifiable certificate of analysis (COA).

---